1 / 6

INTRINSIC RV Trial

Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs Trial. INTRINSIC RV Trial. Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky. INTRINSIC RV Trial: Background.

nyssa-garrison
Download Presentation

INTRINSIC RV Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs Trial INTRINSIC RV Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky

  2. INTRINSIC RV Trial: Background • The goal of the trial was to evaluate dual vs. single chamber pacing among patients implanted with an internal cardioverter defibrillator (ICD) for standard indications. Presented at HRS 2006

  3. INTRINSINC RV Trial: Study Design 988 patients, standard indications for ICD implantation, implanted with a VITALITY AVT ICD programmed to dual chamber rate adaptive pacemaker (DDDR) mode Randomized. 22% female, mean age 63 years, mean follow-up 1 year 67% of patients had coronary artery disease, 78% received beta-blockers, 64% received ACE-inhibitors and 50% received diuretics Patients with RV pacing ≤20% were randomized Continued programming of DDDR AV search hysteresis (AVSH) 60-130 n=502 Reprogramming to VVI-40 n=486 • Primary Endpoint: All-cause mortality or hear failure hospitalization through one year, evaluated for non-inferiority Presented at HRS 2006

  4. INTRINSIC RV Trial: Primary Endpoint Primary endpoint of death or heart failure hospitalization • The primary endpoint of death or heart failure hospitalization occurred in 6.4% of the DDDR AVSH group and 9.5% of VVI-40 group, meeting the threshold for non-inferiority. • For superiority of DDDR AVSH, p=0.072 and the risk ratio was 0.67. Presented at HRS 2006

  5. INTRINSIC RV Trial: All – Cause Mortality Primary endpoint of all-cause mortality p<0.001 • All-cause mortality also met the criteria for non-inferiority (3.6% for DDDR AVSH vs. 5.1% for VVI-40 group, p<0.001 for non-inferiority, p=0.23 for superiority). • During follow-up, RV pacing in the DDDR AVSH group averaged 10%. Presented at HRS 2006

  6. INTRINSIC RV Trial: Summary • Among patients implanted with an ICD for standard indications, use of dual chamber DDDR AVSH pacing was non-inferior to single chamber VVI-40 pacing for death or heart failure hospitalization at one year. • Results of the present trial differ from those of the DAVID trial, which showed treatment with dual-chamber pacing was associated with an increase in mortality or CHF hospitalizations by 1 year compared with ventricular backup pacing in patients with LV dysfunction and standard indications for ICD therapy but not for pacing. • There are several major differences between the trials, including pacing at a lower threshold in the present trial (60 bpm vs. 70bpm in DAVID) and the patient population, which in INTRINSIC RV excluded patients with >20% pacing in the first week Presented at HRS 2006

More Related